| John H Abrams, MD | |
|
11455 N Meridian St, Suite 100, Carmel, IN 46032-1624 | |
| (317) 846-4223 | |
| (317) 846-6063 |
| Full Name | John H Abrams |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 40 Years |
| Location | 11455 N Meridian St, Carmel, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174589584 | NPI | - | NPPES |
| 100354030 | Medicaid | ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 01034454A (Indiana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Indianapolis Ophthalmology Pc | 9335190354 | 6 |
News Archive
A team led by female scientists at the Universities of Bristol and Cambridge has developed an exciting new technique which may lead to a greater understanding of how drugs get in and out of the cells in our bodies. The method identifies the structures that guard the entrance and exits to cells.
Research has shown most frail elderly patients want to maintain quality of life rather than prolong it, but the use of invasive life-sustaining technologies in this population has been increasing.
Multiple system atrophy (MSA) is a neurodegenerative disease with multiple debilitating symptoms. One of them is sleep disorders; however, owing to limited research, little is known about why only some patients are affected, how sleep disorders influence MSA severity, or even how sleep disorders vary across different MSA subtypes.
Genomic medicine is rapidly developing, bringing with its advances promises of individualized genetic information to tailor and optimize prevention and treatment interventions. Genetic tests are already guiding treatments of the human immunodeficiency virus (HIV) and hepatitis c virus (HPC), and emerging research is showing genetic variants may be used to screen for an individual's susceptibility to addiction to a substance, and even inform treatments for addiction.
Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., announced today that it has obtained exclusive rights from the California Institute of Technology to inventions made in the laboratory of David Baltimore, Ph.D. covering methods and compositions for modulating microRNA-146 and microRNA-155.
› Verified 7 days ago
| Entity Name | Indianapolis Ophthalmology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902910359 PECOS PAC ID: 9335190354 Enrollment ID: O20050208000292 |
News Archive
A team led by female scientists at the Universities of Bristol and Cambridge has developed an exciting new technique which may lead to a greater understanding of how drugs get in and out of the cells in our bodies. The method identifies the structures that guard the entrance and exits to cells.
Research has shown most frail elderly patients want to maintain quality of life rather than prolong it, but the use of invasive life-sustaining technologies in this population has been increasing.
Multiple system atrophy (MSA) is a neurodegenerative disease with multiple debilitating symptoms. One of them is sleep disorders; however, owing to limited research, little is known about why only some patients are affected, how sleep disorders influence MSA severity, or even how sleep disorders vary across different MSA subtypes.
Genomic medicine is rapidly developing, bringing with its advances promises of individualized genetic information to tailor and optimize prevention and treatment interventions. Genetic tests are already guiding treatments of the human immunodeficiency virus (HIV) and hepatitis c virus (HPC), and emerging research is showing genetic variants may be used to screen for an individual's susceptibility to addiction to a substance, and even inform treatments for addiction.
Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., announced today that it has obtained exclusive rights from the California Institute of Technology to inventions made in the laboratory of David Baltimore, Ph.D. covering methods and compositions for modulating microRNA-146 and microRNA-155.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John H Abrams, MD 11455 N Meridian St, Suite 100, Carmel, IN 46032-1624 Ph: (317) 846-4223 | John H Abrams, MD 11455 N Meridian St, Suite 100, Carmel, IN 46032-1624 Ph: (317) 846-4223 |
News Archive
A team led by female scientists at the Universities of Bristol and Cambridge has developed an exciting new technique which may lead to a greater understanding of how drugs get in and out of the cells in our bodies. The method identifies the structures that guard the entrance and exits to cells.
Research has shown most frail elderly patients want to maintain quality of life rather than prolong it, but the use of invasive life-sustaining technologies in this population has been increasing.
Multiple system atrophy (MSA) is a neurodegenerative disease with multiple debilitating symptoms. One of them is sleep disorders; however, owing to limited research, little is known about why only some patients are affected, how sleep disorders influence MSA severity, or even how sleep disorders vary across different MSA subtypes.
Genomic medicine is rapidly developing, bringing with its advances promises of individualized genetic information to tailor and optimize prevention and treatment interventions. Genetic tests are already guiding treatments of the human immunodeficiency virus (HIV) and hepatitis c virus (HPC), and emerging research is showing genetic variants may be used to screen for an individual's susceptibility to addiction to a substance, and even inform treatments for addiction.
Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., announced today that it has obtained exclusive rights from the California Institute of Technology to inventions made in the laboratory of David Baltimore, Ph.D. covering methods and compositions for modulating microRNA-146 and microRNA-155.
› Verified 7 days ago
Dr. Kevin Enpei Lai, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 10300 N Illinois St Ste 1000, Carmel, IN 46290 Phone: 317-805-2240 | |
Derek T Sprunger, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 201 Pennsylvania Pkwy Ste 100, Carmel, IN 46280 Phone: 317-817-1333 | |
Stephen Roth Klapper, MD FACS Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 11900 N Pennsylvania St, Suite 104, Carmel, IN 46032 Phone: 317-818-1000 Fax: 317-818-1001 | |
Dr. Jerry Richard Myers, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 13405 Cherry Tree Rd, Carmel, IN 46033 Phone: 317-844-1436 | |
Dr. Mark Matson Kaehr, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 10585 N Meridian St Ste 100, Carmel, IN 46290 Phone: 317-571-1501 Fax: 317-571-4806 | |
Dr. Jennifer Marie Nottage, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 10300 N Illinois St, Carmel, IN 46290 Phone: 317-817-1765 |